Poroid hidradenoma of the eyelid: a case report - Summary - MDSpire

Poroid hidradenoma of the eyelid: a case report

  • By

  • Christian Nieves-Rios

  • José J. López-Fontanet

  • Juan Serrano-Olmo

  • Joseph Campbell

  • May 7, 2026

Share

Objective:

To report a rare case of poroid hidradenoma (PH) located on the eyelid, emphasizing its rarity, and discuss its clinical presentation, diagnosis, and treatment.

Key Findings:
  • PH is a rare, benign neoplasm originating from eccrine sweat glands, typically presenting as a painless subcutaneous mass.
  • Histopathological evaluation confirmed the diagnosis of PH, showing well-defined solid and cystic elements.
  • The patient experienced irritation and pruritus associated with the lesion.
  • No recurrence was observed at the 3-month follow-up.
Interpretation:

The case highlights the diagnostic challenges of PH in atypical locations such as the eyelids, emphasizing the importance of histological examination for accurate diagnosis and its implications for clinical practice.

Limitations:
  • Limited follow-up duration (3 months) may not provide insight into long-term outcomes.
  • Previous lesion history on the same eyelid complicates recurrence assessment due to lack of prior pathology report.
  • The atypical presentation may lead to misdiagnosis, underscoring the need for awareness among healthcare providers.
Conclusion:

Surgical excision remains the standard treatment for PH, and awareness of its ocular manifestations is essential for timely diagnosis and management by healthcare professionals.

Original Source(s)

Poroid hidradenoma of the eyelid: a case report

  • by Christian Nieves-Rios, José J. López-Fontanet, Juan Serrano-Olmo, Joseph Campbell

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...